Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin for ovarian protection during chemotherapy in premenopausal women with hormone receptor-negative early breast cancer
ACTRN12606000075583Phase 3Completed
- Sponsor
- Breast Cancer Trials
- Start
- Jun 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Rate of ovarian failure at 2 years. Started Jun 2006; status: completed.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000075583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000075583.